Safety and Efficacy Study of WeFlow-JAAA Stent Graft System for Complex Abdominal Aortic Aneurysm(GREAT Study)

Exclusion Criteria

• •1. Patients with ruptured abdominal aortic aneurysm, pseudoaortic aneurysm and dissecting aortic aneurysm with hemodynamic instability;
• •2. Infectious aortic disease, Takayasu arteritis, Marfan syndrome (or other connective tissue diseases);
• •3. Severe stenosis, calcification and mural thrombosis in the proximal anchoring area of the stent;
• •4. Other vascular diseases need to be intervened in the same operation (such as coronary artery and carotid artery) and the postoperative drug treatment scheme is affected;
• •5. There is a history of myocardial infarction, TIA or cerebral infarction in recent 3 months;
• •6. The subject has a history of abdominal aortic surgery or endovascular repair;
• •7. Patients with severe liver, kidney, lung and cardiac dysfunction before operation \[subjects with serum creatinine level \> 150umol / L; alanine aminotransferase (ALT) or aspartate aminotransferase (AST) exceeds 5 times the upper normal limit; total serum bilirubin (STB) subjects who exceed 2 times the upper limit of normal; subjects whose left ventricular ejection fraction is less than 50% by color Doppler echocardiography.\];
• •8. Patients with acute systemic infection;
• •9. Patients with contraindications to antiplatelet agents and anticoagulants;
• •10. Subjects are allergic to contrast agents, anesthetics, stents and conveyor materials;
• •11. Subjects cannot tolerate anesthesia;
• •12. Subjects Women who are pregnant or lactating or who cannot use contraception during the trial;
• •13. Subjects whose life expectancy is less than 12 months (such as advanced malignant tumor);
• •14. Subjects have participated in clinical trials of other drugs or devices in the same period;
• •15. The researchers determine that the subjects' vascular conditions affect the revascularization of branch arteries or are combined with other diseases and are not suitable to participate in this study.